Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
WARNING
CYTOKINE RELEASE SYNDROME
Cytokine Release Syndrome (CRS), which may be severe or life-threatening, occurred in patients receiving TECELRA. At the first sign of CRS, immediately evaluate patient for hospitalization and institute treatment with supportive care. Ensure that healthcare providers administering TECELRA have immediate access to medications and resuscitative equipment to manage CRS [see Preparation And Administration, and WARNINGS AND PRECAUTIONS].
TECELRA (afamitresgene autoleucel) is a melanoma-associated antigen A4 (MAGEA4)- directed genetically modified autologous T cell immunotherapy product consisting of CD4 and CD8 positive T cells transduced with a self-inactivating lentiviral vector (LV) expressing an affinity-enhanced T cell receptor (TCR) specific for the human MAGE-A4.
Autologous T cells transduced with MAGE-A4-c1032 LV express the affinity-enhanced TCR on the cell surface. The TCR recognizes an HLA-A*02 restricted MAGE-A4 peptide. MAGE-A4 is an intracellular cancer-testis antigen that has restricted expression in normal tissues and is expressed in synovial sarcoma.
TECELRA is prepared from the patient’s peripheral blood mononuclear cells (PBMCs), which are obtained via a standard leukapheresis procedure. The PBMCs are enriched for T cells and are then transduced with a replication-incompetent LV containing the MAGE-A4 TCR transgene. The transduced T cells are expanded, washed, formulated into a suspension, and cryopreserved. The product must pass a sterility test before release and shipping as a frozen suspension in one or more infusion bag(s). The product is thawed prior to infusion back into the patient [see Preparation And Administration, HOW SUPPLIED]. The drug product formulation contains 5% dimethyl sulfoxide (DMSO).
TECELRA is a melanoma-associated antigen A4-(MAGE-A4)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices.
This indication is approved under accelerated approval based on overall response rate and durability of response [see Clinical Studies]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
For autologous use only. For intravenous use only.
The recommended dose is between 2.68 x 109 to 10 x 109 MAGE-A4 T cell receptor (TCR) positive T cells administered as a single intravenous infusion.
TECELRA is provided as a single dose for infusion in one or more infusion bag(s). Verify the number of bags received for the indicated dose prior to preparation for infusion.
Plan for TECELRA to arrive prior to beginning lymphodepleting chemotherapy. Ensure storage conditions in vapor phase of liquid nitrogen (≤ -130°C).
TECELRA is shipped directly to the healthcare facility in the vapor phase of a liquid nitrogen shipper. Upon receipt of TECELRA confirm the patient’s identifiers on the metal cassette and product bag.
Inspect the product for obvious signs of damage and contact Adaptimmune at 1-855- 24MYADAP (1-855-246-9232) if any anomalies are identified at the time of receipt.
Transfer TECELRA in the original packaging, containing the cassette(s) protecting the infusion bag(s), to onsite storage at ≤ -130°C before the shipper expires.
Store TECELRA in a manner that is consistent with HOW SUPPLIED. If unforeseen circumstances prevent proper storage of TECELRA consistent with How Supplied/Storage and Handling (16), contact Adaptimmune at 1- 855-24MYADAP (1-855-246-9232) to arrange for return shipment.
Confirm availability of TECELRA at the healthcare facility prior to starting the lymphodepleting chemotherapy regimen.
Match the patient’s identity with the patient identifiers on the TECELRA cassette(s) and infusion bag(s). Do not infuse TECELRA if the information on the patient-specific label(s) does not match the intended patient.
Administer a lymphodepleting chemotherapy regimen of fludarabine 30 mg/m2/day intravenously for 4 days starting on the seventh day before TECELRA infusion (Day-7 to Day -4) and cyclophosphamide 600 mg/m2/day intravenously for 3 days starting the seventh day before TECELRA infusion (Day -7 to Day -5).
Refer to fludarabine prescribing for information on fludarabine dosage in patients with renal impairment.
Short-acting or pegylated granulocyte-colony stimulating factor (G-CSF) may be administered at the discretion of the physician, and according with institutional standards, from 24 hours after last day of lymphodepleting chemotherapy (from Day -3) until resolution of neutropenia.
Premedication
Premedicate with an H1-antihistamine and acetaminophen according to institutional standard practice, approximately 30-60 minutes prior to TECELRA infusion.
Avoid prophylactic systemic corticosteroids, as it may interfere with the activity of TECELRA.
Do not thaw the product until it is ready to be used. Coordinate the timing of TECELRA thaw and infusion. Confirm infusion time in advance and adjust the start time of TECELRA thaw such that it will be available for infusion when the patient is ready.
A TECELRA dose may be contained in one or more infusion bag(s). Verify the number of bags received for the indicated dose prior to preparation of TECELRA for infusion. If more than one bag will be infused for the treatment dose, thaw and administer the contents of each infusion bag completely before proceeding to thaw and infuse the contents of the next infusion bag.
TECELRA is a cell suspension for intravenous infusion. A single dose of TECELRA contains 2.68 x 109 to 10 x 109 MAGE-A4 TCR positive T cells in one or more infusion bag(s) [see HOW SUPPLIED].
TECELRA is supplied in one or more infusion bag(s) containing a frozen suspension of genetically modified autologous T cells in 5% DMSO. Each TECELRA infusion bag is individually packed in a metal cassette. Product and patient-specific labels are located on both the product infusion bag(s) and the protective shipping cassette(s).
Each infusion bag (250ml) is contained within a protective metal cassette (NDC 83205- 0001-2).
TECELRA is shipped in a liquid nitrogen dry vapor shipper at less than or equal to - 130°C.
Store TECELRA in the original packaging, containing the cassette(s) protecting the infusion bag(s), in the vapor phase of liquid nitrogen at less than or equal to -130°C.
Manufactured by: Adaptimmune, LLC 351 Rouse Boulevard Philadelphia, PA 19112. Revised: Aug 2024
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety data described in this section reflects the exposure to TECELRA in 44 patients with advanced synovial sarcoma treated in the SPEARHEAD-1 clinical trial (Cohort 1). Patients with synovial sarcoma received TECELRA across a dose of 2.68 x 109 to 10 x 109 MAGE-A4 TCR positive T cells [see Clinical Studies].
Serious adverse reactions occurred in 52% of patients with synovial sarcoma. The most common serious adverse reactions (occurring in ≥ 5%) included CRS (9%) and pleural effusion (7%).
Table 1 summarizes adverse r eactions that occurred in at least 10% of patients.
Table 1. Adverse Reactions Occurring in ≥10% of Patients in SPEARHEAD-1 (Cohort 1)/
| SOC Grouped Term |
(N=44) | |
| All Grades n (%) |
Grade ≥ 3 n (%) |
|
| Investigations | ||
| Weight decreaseds | 5 (11) | 1 (2) |
| Gastrointestinal disorders | ||
| Nausea | 29 (66) | 1 (2) |
| Vomiting | 16 (36) | 0 (0) |
| Constipation | 14 (32) | 0 (0) |
| Abdominal pain | 11 (25) | 2 (5) |
| Diarrhea | 9 (21) | 0 (0) |
| General disorders and administration site conditions | ||
| Fatigue | 15 (34) | 0 (0) |
| Pyrexia | 14 (32) | 2 (5) |
| Non-cardiac chest pain | 10 (23) | 1 (2) |
| Chills | 7 (16) | 0 (0) |
| Edema | 9 (21) | 0 (0) |
| Asthenia | 7 (16) | 1 (2) |
| Chest pain | 6 (14) | 0 (0) |
| Immune system disorders | ||
| Cytokine Release Syndromea | 33 (75) | 1 (2) |
| Infections and infestations | ||
| Any infectionb | 14 (32) | 6 (14) |
| Nervous system disorders | ||
| Headache | 8 (18) | 1 (2) |
| Dizziness | 5 (11) | 0 (0) |
| Metabolism and nutrition disorders | ||
| Decreased appetite | 10 (23) | 1 (2) |
| Musculoskeletal and connective tissue disorders | ||
| Back pain | 9 (21) | 2 (5) |
| Pain in extremity | 6 (14) | 0 (0) |
| Respiratory, thoracic, and mediastinal disorders | ||
| Dyspnea | 11 (25) | 2 (5) |
| Cough | 8 (18) | 0 (0) |
| Vascular disorders | ||
| Hypotension | 9 (21) | 0 (0) |
| Hypertension | 7 (16) | 1 (2) |
| Cardiac disorders | ||
| Sinus Tachycardia/ Tachycardia | 9 (21) | 0 (0) |
| Skin and subcutaneous tissue disorders | ||
| Alopecia | 6 (14) | 0 (0) |
| aAs per American Society for Transplantation and Cellular Therapy (ASTCT) criteria1 bAny infection includes all infection terms under the ‘Infections and infestations’ System Organ Class |
||
Other clinically important adverse reactions occurring in patients receiving TECELRA include Grade 1 ICANS reported in one patient (2%).
Table 2. Laboratory Abnormalitiesa Worsened from Baseline in ≥10% of Patients in SPEARHEAD-1 (Cohort 1)/
| Laboratory Abnormalities | N=44 | |
| All Grades n (%) |
Grade 3 or 4 n (%) |
|
| Lymphocyte count decreased | 43 (98) | 43 (98) |
| Neutrophil count decreased | 42 (96) | 40 (91) |
| White blood cell decreased | 42 (96) | 38 (86) |
| Red blood cell decreased | 42 (96) | 14 (32) |
| Platelet count decreased | 36 (82) | 9 (21 |
| Alanine aminotransferase increased | 20 (46) | 2 (5) |
| Grading based on NCI CTCAE version 5.0. aAbnormalities are laboratory values that were considered an adverse event |
||
None
Included as part of the "PRECAUTIONS" Section
Cytokine release syndrome (CRS), including potentially life-threatening reaction has been observed following administration of TECELRA. CRS occurred in 75% of patients, 2% of whom had Grade ≥ 3 CRS. The median time to onset was 2 days (range: 1 to 5 days) and the median time to resolution was 3 days (range: 1 to 14 days). The most common symptoms were fever (97%), tachycardia (52%), hypotension (30%), nausea/vomiting (21%) and headache (15%) [see ADVERSE REACTIONS]. Management for CRS (including Grade 1) was tocilizumab (55%). Thirteen patients received one dose and five patients received more than one dose. Of the five patients who received more than one dose of tocilizumab, two patients received dexamethasone in addition to tocilizumab.
Ensure that healthcare providers administering TECELRA have immediate access to medications and resuscitative equipment to manage CRS. Ensure patients are euvolemic prior to initiating the infusions.
During and following TECELRA administration, closely monitor patients for signs and symptoms of CRS. Following treatment with TECELRA, monitor patients for at least 7 days at the healthcare facility for CRS. Continue to monitor patients for CRS for at least 4 weeks following treatment with TECELRA. Counsel patients to seek medical attention should signs or symptoms of CRS occur. At the first sign of CRS, immediately evaluate patient for hospitalization and institute treatment with supportive care based on severity and consider further management per current practice guidelines.
Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS) has been observed following administration of TECELRA. One patient (2%) had Grade 1 ICANS. Time to onset was two days and time to resolution was one day. Symptoms included mild mental status changes. Other symptoms may include disorientation to time and place, mild drowsiness, mild inattention. Severe symptoms may include altered level of consciousness, seizures, cerebral edema, impairment of cognitive skills, progressive aphasia, motor weakness.
Ensure that healthcare providers administering TECELRA have immediate access to medications and resuscitative equipment to manage ICANS.
During and following TECELRA administration, closely monitor patients for signs and symptoms of ICANS. Following treatment with TECELRA, monitor patients for at least 7 days at the healthcare facility for ICANS. Continue to monitor patients for ICANS for at least 4 weeks following treatment with TECELRA. Counsel patients to seek medical attention should signs or symptoms of ICANS occur. At the first sign of ICANS, immediately evaluate patients for hospitalization and institute treatment with supportive care based on severity and consider further management per current practice guidelines.
Due to the potential for neurologic events, including dizziness and presyncope, patients receiving TECELRA are at risk for altered or decreased coordination in the 4 weeks following infusion.
Advise patients to refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery, during this initial period.
Patients may exhibit severe cytopenias, including neutropenia and thrombocytopenia [see ADVERSE REACTIONS].
Patients exhibited anemia, neutropenia, and/or thrombocytopenia for several weeks following lymphodepleting chemotherapy and TECELRA infusion. Patients with Grade ≥ 3 cytopenia not resolved by week 4 included anemia (9%), neutropenia (11%), and thrombocytopenia (5%). The median time to resolution was 7.3 weeks (range: 6.1 to 8.4 weeks) for anemia, 9.3 weeks (range: 6.4 to 12.3 weeks) for neutropenia and 6.3 weeks (range: 6.1 to 6.4 weeks) for thrombocytopenia.
Monitor blood counts after TECELRA infusion. Manage cytopenia with growth factor and blood product transfusion according to local institutional guidelines/clinical practice.
Infections may occur following lymphodepleting chemotherapy and TECELRA infusion. Infections (all grades) occurred in 32% of patients with synovial sarcoma. Grade 3 or higher infections occurred in 14% of patients.
Do not administer TECELRA to patients with active infections and/or inflammatory disorders.
Monitor patients for signs and symptoms of infection before and after TECELRA infusion and treat patients appropriately.
Febrile neutropenia was observed in patients after TECELRA infusion and may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad-spectrum antibiotics, fluids and other supportive care, as medically indicated.
Viral reactivation has occurred in patients following treatment with TECELRA. Perform screening for Epstein-Barr Virus, Cytomegalovirus, Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus, and any other infectious agents if clinically indicated. Consider antiviral therapy to prevent viral reactivation per local guidelines.
Patients treated with TECELRA may develop secondary malignancies or recurrence of their cancer. Monitor for secondary malignancies.
In the event that a secondary malignancy occurs, contact Adaptimmune at 1-855- 24MYADAP (1-855-246-9232) to obtain instructions on patient samples to collect for testing.
Serious hypersensitivity reactions, including anaphylaxis, may occur due to dimethyl sulfoxide (DMSO) in TECELRA. Observe patients for hypersensitivity reactions during infusion.
The lentiviral vector used to make TECELRA has limited, short spans of genetic material which are identical to HIV. Therefore, some commercial HIV nucleic acid tests may yield false-positive results in patients who have received TECELRA.
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Discuss the following with the patient:
Advise patients for the need to:
No carcinogenicity or genotoxicity studies have been conducted with TECELRA.
A genomic insertion site analysis was performed on TECELRA products from five patients. There was no evidence for preferential integration near genes of concern. No studies have been conducted to evaluate the effects of TECELRA on fertility.
There are no available data with TECELRA use in pregnant women. No animal reproductive and developmental toxicity studies have been conducted with TECELRA to assess whether it can cause fetal harm when administered to a pregnant woman. It is not known if TECELRA has the potential to be transferred to the fetus and cause fetal toxicity. Therefore, TECELRA is not recommended for women who are pregnant, and pregnancy after TECELRA administration should be discussed with the treating physician. Report all pregnancies following treatment with TECELRA to Adaptimmune at 1-855-24MYADAP (1-855-246-9232).
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
There is no information regarding the presence of TECELRA in human milk, the effect on the breastfed infant, and the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for TECELRA and any potential adverse effects on the breastfed infant from TECELRA or from the underlying maternal condition.
Verify pregnancy status of females with reproductive potential prior to starting treatment with TECELRA.
here are insufficient exposure data to provide a recommendation concerning duration of contraception following treatment with TECELRA.
The safety and effectiveness of TECELRA have not been established in pediatric patients.
Of the 44 patients with synovial sarcoma in the SPEARHEAD-1 study that received TECELRA, 6.8% were 65 years of age or older. Clinical studies of TECELRA did not include sufficient numbers of patients aged 65 and over to conclude whether they respond differently from younger patients.
No Information Provided
DO NOT use TECELRA in adults who are heterozygous or homozygous for HLAA* 02:05P.
TECELRA is a genetically modified autologous T cell immunotherapy consisting of CD4 and CD8 positive T cells transduced with a self-inactivating LV to express an affinityenhanced TCR specific for human MAGE-A4 on the cell surface.
The TCR recognizes an HLA-A*02 restricted MAGE-A4 peptide. MAGE-A4 is an intracellular cancer-testis antigen that has restricted expression in normal tissues and is expressed in synovial sarcoma. Antigen-specific activation of TECELRA via TCRpeptide- HLA-A*02 complex results in T cell proliferation, cytokine secretion, and killing of MAGE-A4/HLA-A*02 expressing synovial sarcoma cells.
In patients with synovial sarcoma who were treated with TECELRA, serum concentrations of cytokines and other soluble factors involved in cellular homeostasis, T cell activation, and inflammation (e.g. IFNγ, IL-6, IL-8, IL-15, and IL-2Rα) increased post-infusion, peaking between Days 3-8.
TECELRA exhibited an initial engraftment and expansion phase followed by contraction, and then persistence. High inter-individual variability was observed.
The pharmacokinetics of TECELRA in patients with synovial sarcoma are summarized in Table 3.
Table 3. Pharmacokinetics of Afamitresgene Autoleucel in SPEARHEAD-1 (Cohort 1)a
| PK Parameter | N | Statistics | Value |
| tmax (day) | 44 | Median (range) | 7 (1-89) |
| Cmax (DNA copies/μg) | 44 | Geometric mean (CV%) | 189269 (109.1%) |
| AUC0-7D (day*DNA copies/μg) | 44 | Geometric mean (CV%) | 729653 (110.8%) |
| AUC0-28D (day*DNA copies/μg) | 41 | Geometric mean (CV%) | 3074205 (164.7%) |
| AUC0-3M (day*DNA copies/μg) | 35 | Geometric mean (CV%) | 4988965 (242.7%) |
| AUC0-6M (day*DNA copies/μg) | 33 | Geometric mean (CV%) | 6784047 (313.4%) |
| aAll patients received a dose within the range of 2.68 x 109 to 10 x 109 MAGE-A4 TCR positive T cells. | |||
The pharmacokinetics of afamitresgene autoleucel (Cmax, AUC0-7D, AUC0-28D, AUC0-3M, AUC0-6M) were not impacted by body weight, body mass index, sex, age (range: 19 to 76 years), and baseline tumor sum of longest diameter (SLD).
Hepatic and renal impairment studies of TECELRA were not conducted.
The efficacy of TECELRA was evaluated in a multicenter, single-arm, open-label clinical trial (SPEARHEAD-1, Cohort 1). The study enrolled HLA-A*02:01P, HLA-A*02:02P, HLA-A*02:03P, and HLA-A*02:06P allele positive patients with inoperable or metastatic synovial sarcoma who had received prior systemic therapy with either doxorubicin and/or ifosfamide and whose tumor expressed the MAGE-A4 tumor antigen. The study included patients with measurable disease according to RECIST v1.1, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and glomerular filtration rate (GFR) ≥ 60 mL/min. The study excluded patients with HLA-A*02:05P in either allele, patients on systemic corticosteroids for at least 14 days prior to leukapheresis and lymphodepletion, and recipients of allogeneic hematopoietic stem cell transplants.
Patients underwent high resolution HLA typing at a centralized testing site and had tumor samples tested for MAGE-A4 expression by an immunohistochemistry (IHC) clinical trial assay at a centralized testing site. Patients underwent leukapheresis for collection of autologous cells for processing and manufacture into TECELRA. Risk of manufacturing or delivery failure was 8% in the clinical trial (4/52) patients.
Patients received lymphodepleting chemotherapy with fludarabine 30 mg/m2/day for 4 days (Day -7 to Day -4) and cyclophosphamide 600mg/ m2/day for 3 days (Day -7 to Day -5). Patients with GFR 60-79 mL/min received an adjusted fludarabine dose of 20 mg/m2/day. TECELRA was administered as a single intravenous (IV) infusion on Day 1. Fifty-two (52) patients were enrolled and underwent leukapheresis, eight of whom did not receive TECELRA due to the following: death (n=3), loss of eligibility prior to lymphodepleting chemotherapy (n=3), withdrawal by patient (n=1), investigator decision (n=1). Forty-five (45) patients with synovial sarcoma received lymphodepletion and one patient withdrew consent before receiving TECELRA. There were 44 patients with synovial sarcoma who received a single infusion of TECELRA.
Among the efficacy analysis population demographic characteristics were as follows: median age was 41 years (range: 19 to 73 years), 50% were female, and 89% were White, and 96% were HLA-A*02:01P.
The median number of prior lines of systemic therapies was three (range: 1 to 12 lines). Prior therapies included ifosfamide (100%), doxorubicin (95%), pazopanib (48%), trabectedin (25%), dacarbazine (11%), and gemcitabine (11%). Between leukapheresis and initiation of lymphodepletion, 16 (36%) of the 44 patients received bridging therapy. The most commonly used bridging therapy was pazopanib (69%). The median dose of TECELRA was 8x109 MAGE-A4 TCR positive T cells (range: 2.68 x 109 to 9.99 x109).
The major efficacy outcome measure was overall response rate (ORR) according to RECISTv1.1 evaluated by independent review committee (IRC). Duration of response (DOR) was an additional outcome measure.The ORR results are presented in Table 4.
Table 4. Efficacy Results* for SPEARHEAD-1 (Cohort 1).
| Endpoint | TECELRA Treated Population N=44 |
| Overall Response Rate | 43.2% |
| (95% CI)1 | (28.4, 59.0) |
| Complete response rate, n (%) | 2 (4.5%) |
| Partial response rate, n (%) | 17 (38.6%) |
| Median Duration of Response# in months | 6.0 |
| (95% CI)2 | (4.6, NR) |
| Min, Max | 1.9, 36.1+ |
| Patients with DoR ≥ 6 months, %2 | 45.6% |
| Patients with DoR ≥ 12 months, %2 | 39.0% |
| CI= confidence interval; NR= not reached. *Efficacy assessment was by independent review committee according to Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. #Duration of response only applies to patients with a complete or partial response. 1Two-sided 95% confidence interval based on exact Clopper-Pearson (exact Binomial) method. 2Two-sided 95% confidence interval and % of patients with response duration >6 and >12 months based on Kaplan-Meier method. |
|
The median time to response from TECELRA treatment was 4.9 weeks (95% CI: 4.4 weeks, 8 weeks) by Kaplan Meier estimation.
TECELRA®
(pronounced tuh-sel-ruh)
(afamitresgene autoleucel)
Read this Medication Guide before you start your TECELRA treatment. Talk with your healthcare provider if you have questions about your health condition or treatment. Reading this Medication Guide does not take the place of talking with your healthcare provider about your treatment.
What is the most important information I should know about TECELRA?
You will likely be in a hospital before and after getting TECELRA.
TECELRA may cause side effects that can be severe or life-threatening. Call your healthcare provider or get emergency help right away if you get any of the following:
Tell all your healthcare providers that you were treated with TECELRA.
What is TECELRA?
TECELRA is a medicine, called a genetically modified autologous T cell immunotherapy, that is used to treat synovial sarcoma. It is used when other kinds of treatment do not work.
TECELRA is different from other cancer medicines because it is made from your own white blood cells that are made to recognize and attack your cancer cells.
Your healthcare provider will perform tests to see if TECELRA is right for you.
Before you get TECELRA, tell your healthcare provider about all your medical problems, including:
Tell your healthcare provider about all the medicines you take,including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How will I get TECELRA?
Since TECELRA is made from your own white blood cells, your blood will be collected by a process called “leukapheresis” (loo-kah-fur-ee-sis). This gets sent to a company to make the TECELRA for you.
It takes about 6 weeks to get your TECELRA back, but the time may vary.
While your TECELRA is being made, your healthcare provider may give you other medicines to stabilize your cancer.
Before you get your TECELRA, you will get 4 days of chemotherapy to prepare your body.
When your TECELRA is ready, you get a tube (intravenous catheter) placed into your vein and your dose of TECELRA will be given in one or more infusion bags. The infusion may take up to 60 minutes for each infusion bag.
After getting TECELRA, you will be monitored daily at the healthcare facility, for at least 7 days after the infusion.
You should plan to stay close to a healthcare facility for at least 4 weeks. Your healthcare provider will check to see that your treatment is working and help you with any side effects that may occur.
Your healthcare provider will do blood tests to follow your progress. It is important that you have your blood tested. If you miss a scheduled appointment for your collection of blood, call your healthcare provider as soon as possible to reschedule.
What are the possible or reasonably likely side effects of TECELRA?
The most common side effects of TECELRA include:
Do not drive, operate heavy machinery, or do other activities that could be dangerous for at least 4 weeks after you get TECELRA.
Do not donate blood, organs, tissues, or cells for transplantation.
What are the ingredients in TECELRA?
Active ingredient: afamitresgene autoleucel
Inactive ingredients: Dimethyl Sulfoxide (DMSO)
